Accessibility Menu
Vivos Therapeutics logo

Vivos Therapeutics(NASDAQ) VVOS

Market Cap$5.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-99%
1 Year-92%
1 Month-10%
$0.41
+4.27%
+0.02Today
Vivos Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.402026-07-27
Vivos Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.99%USD 0.412026-07-20
1 month-9.96%USD 0.452026-06-26
3 month-52.55%USD 0.852026-04-28
Year to date-80.15%USD 2.032025-12-31
1 year-92.31%USD 5.242025-07-25
3 year-94.27%USD 7.042023-07-28
5 year-99.48%USD 78.252021-07-28
Since inception-99.83%USD 224.752020-12-11

Vivos Therapeutics Financials at a Glance

Market Cap

$5.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$19.57M

Net Income (TTM)

-$25.12M

EPS (TTM)

-$2.31

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$0.41

Volume

131,132

Open

$0.42

Previous Close

$0.40

Daily Range

$0.39 - $0.42

52-Week Range

$0.36 - $5.69

Estimated Earnings Date

Aug 18, 2026

VVOS News

Foolcom-Featured.png

Vivos Reports 7% Sales Drop

Motley Fool Markets TeamAug 20, 2025
featured-earnings-leadership-highlights.png

Vivos Therapeutics Unveils New Model

Motley Fool Markets TeamAug 19, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vivos Therapeutics

Vivos helps adults with sleep and breathing problems using dental devices. Its main products treat snoring and sleep apnea without surgery or drugs. These solutions are used by dentists and sleep centers to improve patient sleep quality.

Gadgets for Good Sleep: What Vivos Sells

  • Product revenue (49% of Q2 2025 revenue): Custom dental devices and guides for adults with sleep apnea or snoring, used mainly by dentists.
  • Therapeutic Programs: Structured treatment plans for children and adults, including growth guidance and airway expansion.
  • Service revenue (51% of Q2 2025 revenue): Includes home sleep tests, screening tools, and related services for both adults and children.
  • Support Services: Training, billing help, and telemedicine therapy for dental and medical professionals.

Growth Spurts and New Beds: Expansion Moves

  • Acquired The Sleep Center of Nevada in June 2025, adding seven sleep clinics.
  • Launched Sleep Optimization teams in 2025 to boost patient capacity at sleep centers.
  • Formed a joint venture with MISleep Solution LLC in July 2025 for sleep center management in Michigan.
  • Shifted from dentist-only sales to direct management and acquisition of sleep centers since 2024.

Why Vivos Is a Bit Different

Vivos combines dental and medical approaches for sleep disorder treatment. Its model now includes direct control of sleep centers, not just dentist partnerships. The company integrates diagnostics, therapy, and device sales under one roof for higher efficiency.

Five Things You Need to Know

  • Q2 2025 revenue was $4M, down 5.8% from Q2 2024.
  • Gross margin fell to 55% in Q2 2025, from 65% a year earlier.
  • Q2 2025 net loss was $5M, compared to $1.9M in Q2 2024.
  • Cash and equivalents were $4.4M as of June 30, 2025.

Bottom Line

Vivos has shifted from selling to dentists to running sleep centers directly. The company faces financial challenges but continues to adapt its business model.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

268

CEO

R. Kirk Huntsman

Website

www.vivos.com

Headquarters

Littleton, CO 80120, US

VVOS Financials

Key Financial Metrics (TTM)

Gross Margin

59.48%

Operating Margin

-115.47%

Net Income Margin

-128.36%

Return on Equity

-2239.18%

Return on Capital

-165.62%

Return on Assets

-100.30%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.89M

Volume

131.13K

Avg. Volume

1.64M

Financials (TTM)

Gross Profit

$11.64M

Operating Income

-$22.60M

EBITDA

-$23.53M

Operating Cash Flow

-$17.48M

Capital Expenditure

-$789.00K

Free Cash Flow

-$18.25M

Cash & ST Invst.

$2.11M

Total Debt

$12.27M

Vivos Therapeutics Performance Analysis

Vivos Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 16,024,000-5.1%
20232023-12-31USD 13,801,000-13.9%
20242024-12-31USD 15,031,0008.9%
20252025-12-31USD 17,443,00016.0%
Vivos Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3026.7%
Q32025-09-3077.6%
Q42025-12-31-43.6%
Q12026-03-3134.4%
Vivos Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -25.908.4%
20232023-12-31USD -11.14-57.0%
20242024-12-31USD -2.22-80.1%
20252025-12-31USD -2.06-7.1%
Vivos Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-22.2%
Q32025-09-3010.9%
Q42025-12-31-51.0%
Q12026-03-3129.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.14M

+70.5%

Gross Profit

$2.61M

+72.6%

Gross Margin

50.67%

N/A

Market Cap

$5.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.89K

N/A

Employees

268

N/A

Net Income

-$7.75M

-100.6%

EBITDA

-$7.30M

-97.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.11M

-9.9%

Total Debt

$12.27M

+776.9%

Accounts Receivable

$1.77M

+146.4%

Inventory

$0.00

N/A

Long Term Debt

$4.17M

+347.3%

Short Term Debt

$8.10M

+1634.3%

Return on Assets

-1.00%

N/A

Return on Invested Capital

-3.18%

N/A

Free Cash Flow

-$6.01M

-53.4%

Operating Cash Flow

-$6.01M

-58.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CODXCo-Diagnostics, Inc.
$2.04-2.86%
OSRHOSR Holdings, Inc.
$0.43+2.44%
ADGMAdagio Medical Holdings, Inc.
$0.48-0.08%
AEMDAethlon Medical, Inc.
$0.56-3.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About VVOS

What is the current price of Vivos Therapeutics?

Vivos Therapeutics is trading at $0.40 per share.

What is the 52-week range for Vivos Therapeutics?

Over the past 52 weeks, Vivos Therapeutics has traded between $0.36 and $5.69.

How much debt does Vivos Therapeutics have?

As of the most recent reporting period, Vivos Therapeutics reported total debt of $12.27M.

How much cash does Vivos Therapeutics have on hand?

Vivos Therapeutics reported $2.11M in cash and cash equivalents in its most recent financial results.

What is Vivos Therapeutics’s dividend yield?

Vivos Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services